✨ Free AI Report
INmune Bio Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview INmune Bio Inc.
Research Preview

INmune Bio Inc.: Business Overview, Financials & Competitive Analysis

INmune Bio is a clinical-stage immunology company focused on developing drugs to reprogram the patient's innate immune system to treat hematologic malignancies, solid tumors, and chronic inflammation. The company oper...

Analyst-debate audio for INmune Bio Inc.

AskCyborg analysts argue the bull and bear cases for INmune Bio Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
INmune Bio Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Clinical-stage biotech with promising multi-platform approach but challenged by trial failures, mounting losses, and...

Read the full analyst-debate transcript →
Industry Clinical-Stage Biotechnology / Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest INmune Bio Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

INmune Bio Inc. Overview

Pro stress-test →

INmune Bio is a clinical-stage immunology company focused on developing drugs to reprogram the patient's innate immune system to treat hematologic malignancies, solid tumors, and chronic inflammation. The company operates three distinct product platforms targeting unmet needs in oncology, neurodegenerative diseases, and inflammatory conditions.

Strategic Profile

Pro stress-test →

The Dominant-Negative TNF (DN-TNF) Platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor (sTNF) without interfering with trans-membrane TNF or TNF receptors. Key development programs include INKmune (Phase 1 for high-risk myelodysplastic syndrome), INB03 (Phase II for breast cancer), and XPro1595 (for Alzheimer's disease and treatment resistant depression).

Competitive Landscape

Pro stress-test →

INmune Bio is a publicly traded clinical-stage biotechnology company competing in the immunotherapy space against larger established players and other clinical-stage biotech firms. The company's precision medicine approach targeting innate immune dysfunction differentiates it from broader immunotherapy platforms, though it faces intense competition from well-capitalized CAR-T and checkpoint inhibitor developers.

Industry Context

INmune Bio Inc. operates in Clinical-Stage Biotechnology / Immunotherapy.

Key facts

Founded: 2015 · Headquarters: Boca Raton, Florida · Revenue: $14,000 (2024)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on INmune Bio Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when INmune Bio Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell ImmunotherapyCell-based cancer immunotherapy→PD-1/PD-L1 Checkpoint InhibitorsCheckpoint inhibitor cancer treatments→TNF InhibitorsAnti-TNF therapies for inflammation→

Compare INmune Bio Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

INmune Bio Inc. operates in Clinical-Stage Biotechnology / Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Clinical-Stage Biotechnology by Cyborg Score

Browse Clinical-Stage Biotechnology / Immunotherapy research →
NEW · MCP server

Ask your AI assistant about INmune Bio Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare INmune Bio Inc. and its top competitor on Cyborg Score”
“What did INmune Bio Inc. do this quarter?”
“Is INmune Bio Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does INmune Bio Inc. do?+
INmune Bio is a clinical-stage immunology company focused on developing drugs to reprogram the patient's innate immune system to treat hematologic malignancies, solid tumors, and chronic inflammation. The company oper...
What is INmune Bio Inc.'s Cyborg Score?+
INmune Bio Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are INmune Bio Inc.'s main competitors?+
Named competitors include CAR-T Cell Immunotherapy, PD-1/PD-L1 Checkpoint Inhibitors, TNF Inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full INmune Bio Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the INmune Bio Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track INmune Bio Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Clinical-Stage Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Adaptive Biotechnologies Corporation7Evommune, Inc.7Monte Rosa Therapeutics, Inc.7PepGen Inc.7Tectonic Therapeutic, Inc.6Adlai Nortye Ltd.6Coya Therapeutics, Inc.6Vigil Neuroscience, Inc.5Cel-Sci Corporation4Cassava Sciences, Inc.Top companies in Clinical-Stage Biotechnology by Cyborg Score